ESR1 and breast carcinoma: Thus in summary, the NPF retained all of the positive estrogenic attributes previously described for SM6Met, namely, ERα antagonism, ERβ agonism and antagonism of E2-induced breast cancer cell proliferation, whereas PF retained only ERα antagonism and antagonism of E2-induced breast cancer cell proliferation, but not ERβ agonism.